Evidence map›Paper›PMID 33727097›Full record

ArticleExperimental neurology2021

Treatment of diabetic peripheral neuropathy with engineered mesenchymal stromal cell-derived exosomes enriched with microRNA-146a provide amplified therapeutic efficacy.

Baoyan Fan, Michael Chopp, Zheng Gang Zhang, Xian Shuang Liu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Baoyan FanDepartment of Neurology, Henry Ford Health System, Detroit, MI 48202, United States of America.
Michael ChoppDepartment of Neurology, Henry Ford Health System, Detroit, MI 48202, United States of America; Department of Physics, Oakland University, Rochester, MI 48309, United States of America.
Zheng Gang ZhangDepartment of Neurology, Henry Ford Health System, Detroit, MI 48202, United States of America.
Xian Shuang LiuDepartment of Neurology, Henry Ford Health System, Detroit, MI 48202, United States of America. Electronic address: xliu2@hfhs.org.
Henry Ford Health System · US

Funding

Translational study of miR-146a gene therapy for diabetic peripheral neuropathyR01DK102861 · NIDDK · HENRY FORD HEALTH SYSTEM · PI LIU, XIANSHUANG · 2015 to 2018
$1.3M
NIDDK NIH HHS R01 DK102861
6 · The paper itself

Abstract

Diabetic peripheral neuropathy (DPN) is one of the most prevalent chronic complications of diabetes mellitus with no effective treatment. We recently demonstrated that mesenchymal stromal cell (MSC)-derived exosomes (exo-naïve) alleviate neurovascular dysfunction and improve functional recovery. MicroRNA (miRNA), one of the exosomal cargos, downregulates inflammation-related genes, resulting in suppression of pro-inflammatory gene activation. In the present study, we developed engineered MSC-exosomes loaded with miR-146a (exo-146a) and compared the therapeutic effects of exo-146a with exo-naïve in diabetic (db/db) mice with DPN. Exo-146a possesses a high loading capacity, robust ability to accumulate in peripheral nerve tissues upon systemic administration, and evokes substantially enhanced therapeutic efficacy on neurological recovery compared with exo-naïve. Treatment of DPN in diabetic mice with exo-146a for two weeks significantly increased and decreased nerve conduction velocity, and thermal and mechanical stimuli threshold, respectively, whereas it took four weeks of exo-naive treatment to achieve these improvements. Compared with exo-naïve, exo-146a significantly suppressed the peripheral blood inflammatory monocytes and the activation of endothelial cells via inhibiting Toll-like receptor (TLR)-4/NF-κB signaling pathway. These data provide a proof-of-concept about both the feasibility and efficacy of the exosome-based gene therapy for DPN. The translation of this approach to the clinic has the potential to improve the prospects for people who suffer from DPN.

Indexed as

AnimalsDiabetes Mellitus, ExperimentalDiabetic NeuropathiesExosomesGenetic TherapyMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceMice, TransgenicMicroRNAsTissue EngineeringTreatment OutcomeMicroRNAsMirn146 microRNA, mouseDiabetic peripheral neuropathyExosomesMesenchymal stromal cellsmicroRNA-146a

Identifiers

PMID33727097
PMCPMC8169562
OpenAlexW3136183120

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.